Dynavax/DVAX

$11.84

-1.41%
-
1D1W1MYTD1YMAX

About Dynavax

Dynavax Technologies Corporation is a commercial-stage biopharmaceutical company, which is engaged in developing and commercializing vaccines. The Company's products include HEPLISAV-B hepatitis B vaccine and CpG 1018. Its HEPLISAV-B ((Recombinant)(Adjuvanted) is indicated for the prevention of infection caused by all known subtypes of the hepatitis B virus in adults 18 years of age and older. HEPLISAV-B is a two-dose hepatitis B vaccine for adults. It also manufactures and sells CpG 1018 adjuvant, the adjuvant used in HEPLISAV-B. It is also engaged in developing a multi-program clinical pipeline leveraging CpG 1018 adjuvant to develop improved vaccines for indications with unmet medical needs. Its Pipeline programs include vaccine candidates under development for shingles, tetanus, diphtheria, and pertussis (Tdap) and plague. Its Shingles vaccine program Z-1018, which is an investigational vaccine candidate being developed for the prevention of shingles in adults aged 50 and older.

Ticker

DVAX

Sector

Healthcare

Trading on

NASDAQ

Industry

Biotechnology & Drugs

CEO

Ryan Spencer

Employees

408

Headquarters

Emeryville, United States

Dynavax Metrics

BasicAdvanced
$1.56B
Market cap
-
P/E ratio
-$0.07
EPS
1.29
Beta
-
Dividend rate
$1.56B
1.28801
$15.15
$10.06
1.88M
13.813
12.957
35.799
35.799
-0.64%
-1.06%
-0.72%
6.72
2.488
2.517
16.181
-67.86%
-103.77%
70.88%

What the Analysts think about Dynavax

Analyst Ratings

Majority rating from 6 analysts.
Buy

Price Targets

Average projection from 4 analysts.
117.48% upside
High $29.00
Low $20.00
$11.84
Current price
$25.75
Average price target

Dynavax Financial Performance

Income StatementBalance sheetCash Flow

Income Statement

Revenues and expenses
0.36% profit margin
QuarterlyAnnual
Q4 23
QoQ growth
Revenue
$55.5M
-20.14%
Net income
$200K
-98.59%
Profit margin
0.36%
-98.24%

Dynavax Earnings Performance

Earnings per share (EPS)

Company profitability
Beat by 766.67%
QuarterlyAnnual
Q1 23
Q2 23
Q3 23
Q4 23
Q1 24
Actual
-$0.19
$0.03
$0.10
-
-
Expected
-$0.13
-$0.09
-$0.02
-$0.01
-$0.02
Surprise
43.4%
-132.7%
-766.67%
-
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. Fundamental data, financials and analyst ratings are sourced from Refinitiv.

Upcoming events

FAQs

What’s the current market cap for Dynavax stock?

Dynavax (DVAX) has a market cap of $1.56B as of April 13, 2024.

What is the P/E ratio for Dynavax stock?

The price to earnings (P/E) ratio for Dynavax (DVAX) stock is 0 as of April 13, 2024.

Does Dynavax stock pay dividends?

No, Dynavax (DVAX) stock does not pay dividends to its shareholders as of April 13, 2024.

When is the next Dynavax dividend payment date?

Dynavax (DVAX) stock does not pay dividends to its shareholders.

What is the beta indicator for Dynavax?

Dynavax (DVAX) has a beta rating of 1.29. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.

What is the Dynavax stock price target?

The target price for Dynavax (DVAX) stock is $25.75, which is 117.48% above the current price of $11.84. This is an average based on projections from 4 analysts, and represents their view of what the stock price could be in 12 or 18 months. This should not be seen as investment advice - Lightyear does not carry out investment research.

Buy or sell Dynavax stock

Buy or sell Dynavax stock

Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.
Start investing